open access

Vol 11, Supp. I (2015)
Case report
Published online: 2016-06-16
Get Citation

Hormonetherapy in palliative treatment using fulvestrant — clinical case report

Ewa Kilar

open access

Vol 11, Supp. I (2015)
CASE REPORTS
Published online: 2016-06-16

Abstract

Hormone therapy as a system treatment is one of the earliest cancer therapeutic treatments. This is indicated by observations of reduced expansion of breast “tumour“ in some women during menopause period and in some women who underwent removal of reproductive organs, which was a reason for this reduced expansion. The structure of the mammary gland in women during the reproduction changes every 2 weeks beyond the period of pregnancy. The above changes are primarily affected by neuro hormonal system. When in the mammary gland, as a result of a number of metabolic changes, occurs cancer transformation altered cells can still be equipped with oestrogens and progesterone receptors as normal cells. Thus for this group of patients the possibility of hormonal medicines’ treatment occurred. There is a similarity in therapeutic properties in the currently created new generation of drugs (monoclonal antibodies) and effects of hormonal drugs . The Priority is a definition of “purpose of its impact” on the receptors or metabolic pathways and consequently its impact on tumour cells’ DNA and partially healthy cells.

Fulvestrant is a drug/medicine which irreversibly blocks oestrogens receptor in cancer cells, and its effectiveness will be presented in the description of the course of treatment of a patient with advanced cancer disease who is under palliative treatment. Good quality of life of the patient in the course of the therapy is also important and fulvestrant provides it.

Abstract

Hormone therapy as a system treatment is one of the earliest cancer therapeutic treatments. This is indicated by observations of reduced expansion of breast “tumour“ in some women during menopause period and in some women who underwent removal of reproductive organs, which was a reason for this reduced expansion. The structure of the mammary gland in women during the reproduction changes every 2 weeks beyond the period of pregnancy. The above changes are primarily affected by neuro hormonal system. When in the mammary gland, as a result of a number of metabolic changes, occurs cancer transformation altered cells can still be equipped with oestrogens and progesterone receptors as normal cells. Thus for this group of patients the possibility of hormonal medicines’ treatment occurred. There is a similarity in therapeutic properties in the currently created new generation of drugs (monoclonal antibodies) and effects of hormonal drugs . The Priority is a definition of “purpose of its impact” on the receptors or metabolic pathways and consequently its impact on tumour cells’ DNA and partially healthy cells.

Fulvestrant is a drug/medicine which irreversibly blocks oestrogens receptor in cancer cells, and its effectiveness will be presented in the description of the course of treatment of a patient with advanced cancer disease who is under palliative treatment. Good quality of life of the patient in the course of the therapy is also important and fulvestrant provides it.

Get Citation

Keywords

estrogen receptors, breast cancer, fulvestrant

About this article
Title

Hormonetherapy in palliative treatment using fulvestrant — clinical case report

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. I (2015)

Article type

Case report

Published online

2016-06-16

Keywords

estrogen receptors
breast cancer
fulvestrant

Authors

Ewa Kilar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl